NCT07712575PHASE1RecruitingAccepts Healthy Volunteers
A Study of V132 in Healthy Older Participants (V132-001)
Merck Sharp & Dohme LLC
Start Date
8/12/2026
Completion Date
6/21/2028
Summary
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
Eligibility Criteria
Age Range: 50 years to 75 years
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
* Is in good health
* Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive)
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
* Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
* Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
Interventions
BIOLOGICAL
V132 Formulation 1
BIOLOGICAL
V132 Formulation 2
BIOLOGICAL
V132 Formulation 3
BIOLOGICAL
PREVNAR 20™
BIOLOGICAL
CAPVAXIVE™
Conditions
Healthy
Locations
Anaheim Clinical Trials ( Site 0006)
Anaheim, California 92801
United States
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida 33009
United States
Research Centers of America ( Hollywood ) ( Site 0009)
Hollywood, Florida 33024
United States
QPS-MRA, LLC-Early Phase ( Site 0001)
South Miami, Florida 33143
United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
Springfield, Missouri 65802
United States
Velocity Clinical Research Lincoln ( Site 0007)
Lincoln, Nebraska 68510
United States
Velocity Clinical Research, Omaha ( Site 0008)
Omaha, Nebraska 68134
United States
Remington-Davis, Inc. ( Site 0005)
Columbus, Ohio 43215
United States
Velocity Clinical Research, Providence ( Site 0010)
East Greenwich, Rhode Island 02818
United States
University of Texas Medical Branch ( Site 0004)
League City, Texas 77573
United States